Cat. No.: HY-N0486

Copy Link Print Information

L-Leucine

(Synonyms: Leucine)

16 Cited Publications

Customer Review

Based on 16 publication(s) in Google Scholar

L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway.

For research use only. We do not sell to patients.

Purity: 98.0%
CAS No.: 61-90-5
Formula: C₆H₁₃NO₂
Molecular Weight:131.17

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

L-Leucine Chemical Structure

CAS No.: 61-90-5

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (16)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway^[1].

IC₅₀ & Target^[1]^[2]

mTORC1

Human Endogenous Metabolite

Microbial Metabolite

All mTOR Isoforms :

All Endogenous Metabolite Isoforms :

All Ligands for E3 Ligase Isoforms :

In Vitro

L-Leucine (10 mM) treatment impairs endocrine progenitor cell development^[1].
In E13.5 rat pancreatic explants, in absence of added L-Leucine, Ngn3 mRNA levels increased after 1 day of culture, peaked on day 3, and then decreased. When L-Leucine is added, a dramatic decrease is observed in Ngn3 mRNA levels. This decrease in Ngn3 mRNA levels was paralleled by a decrease in the number of Ngn3-expressing cells (4728±408 vs. 959±28; P<0.01). Finally, L-Leucine also caused a dose-dependent repressive effect on the mRNA levels of the three genes, namely Ngn3, its target Insm1, and insulin^[1].
Leucine stimulates protein synthesis in skeletal muscle of neonatal pigs by enhancing mTORC1 activation. L-Leucine increases intracellular HIF-1α levels and activates the HIF-1α signaling pathway, and these two effects are mediated by the mTOR signaling pathway. This process results in Ngn3 repression and, consequently, decreases β-cell differentiation^[1].
L-leucine stimulates mTORC1 by through a mechanism that involves the leucyl tRNA synthase promoting the activity of GTP activating proteins that act on mTORC1^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

L-Leucine (24 g/kg diet) combined with Resveratrol (12.5 mg/kg diet) to diet-induced obese (DIO) mice increases adipose Sirt1 activity^[2].
Combination results in significant reductions in body weight, weight gain, visceral adipose tissue mass, fat oxidation and heat production in mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Six-week-old male c57/BL6 mice (fed a high-fat diet with fat to induce obesity)^[1]
Dosage:

24 g/kg diet; Resveratrol (low dose; 12.5 mg/kg diet)
Administration:

6 weeks
Result:

Treatment in combination with Resveratrol (low dose; 12.5 mg/kg diet) resulted in significant reductions in body weight, weight gain, visceral adipose tissue mass, fat oxidation and heat production, and an associated decrease in respiratory exchange ratio (RER), especially in the dark (feeding) cycle.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 61-90-5
Appearance Solid
Molecular Weight 131.17
Formula C₆H₁₃NO₂
Color White to off-white
SMILES

N[C@@H](CC(C)C)C(O)=O
Synonyms

Leucine
Structure Classification
- Amino acids
Initial Source
- Endogenous metabolite
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (16)

All WBIHCIn Vivo Efficacy StudyRT-PCR

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

A two-strata energy flux system driven by a stress hormone prioritizes cardiac energetics. [Abstract]

2025 Sep 26;10(1):315. PMID: 40998786
Pharmacol Res

Dioscin ameliorates murine ulcerative colitis by regulating macrophage polarization. [Abstract]

2021 Oct:172:105796. PMID: 34343656
Redox Rep

The hippo-YAP1/TEAD1-SLC7A5 axis: uncovering a novel therapeutic target for oxalate-induced renal tubular ferroptosis. [Abstract]

2026 Dec;31(1):2643967. PMID: 41833934
J Agric Food Chem

Sestrin 2 Regulates Milk Protein Synthesis through a LAT1/mTOR Pathway. [Abstract]

2025 Dec 17;73(50):31783-31793. PMID: 41329159
Acta Neuropathol Commun

Transaldolase 1 impacts Parkinson's disease pathogenesis via metabolic reprogramming and autophagy-lysosomal pathway. [Abstract]

2025 Nov 4;13(1):223. PMID: 41189023

L-Leucine purchased from MedChemExpress. Usage Cited in: Acta Neuropathol Commun. 2025 Nov 4;13(1):223. [Abstract]

Western blot analysis of p-mTOR, total mTOR, p-TFEB, total TFEB, and β-actin in shNT or shTAL-transfected MN9D cells treated with either PBS or L-Leucine (100 μM; 36 h), a mTORC1 activator.

L-Leucine purchased from MedChemExpress. Usage Cited in: Acta Neuropathol Commun. 2025 Nov 4;13(1):223. [Abstract]

Quantitative analysis of p-mTOR/mTOR and p-TFEB/TFEB ratios demonstrates that TAL1 knockdown decreases mTORC1 activity and TFEB phosphorylation, and this effect is attenuated by L-Leucine (100 μM; 36 h) treatment.
Int J Pharm

Development of a proliposomal pretomanid dry powder inhaler as a novel alternative approach for combating pulmonary tuberculosis. [Abstract]

2024 Aug 18:124608. PMID: 39163929
J Nutr Biochem

Food-derived chlorogenic acid prevents aortic aneurysm and dissection by nutritional restore branched-chain amino acid dyshomeostasis. [Abstract]

2025 Dec 6:150:110211. PMID: 41360205
Exp Neurol

Fidgetin impacts axonal growth and branching in a local mTOR signal dependent manner. [Abstract]

2023 Mar:361:114315. PMID: 36586551

L-Leucine purchased from MedChemExpress. Usage Cited in: Exp Neurol. 2023 Mar:361:114315. [Abstract]

Representative immunostaining results of mcherry (in Red), GFAP (in Green). Spinal cord was treated with Ctrl or Fign shRNA. Propriospinal neurons were label with mcherry. 1 day after SCI (spinal cord injury), L- leucine (10 mg/mL) or saline was administered by tail vein injection at a dose of 1 mg/30 g body weight every other day for 28 days.
J Mol Med (Berl)

mTOR-FABP4 signal is activated in brain arteriovenous malformations in humans. [Abstract]

2022 Sep;100(9):1287-1297. PMID: 35876909
FASEB J

L-leucine promotes axonal outgrowth and regeneration via mTOR activation. [Abstract]

2021 May;35(5):e21526. PMID: 33813773
Brain Res Bull

Delayed simvastatin treatment improves neurological recovery after cryogenic traumatic brain injury through downregulation of ELOVL1 by inhibiting mTOR signaling. [Abstract]

2024 Sep 5:111072. PMID: 39243948
Mol Pain

Inhibition of mTOR/S6K1/Gli1 signaling alleviates morphine-induced thermal hyperalgesia and tolerance. [Abstract]

2025 Jan-Dec:21:17448069251376198. PMID: 40968661

L-Leucine purchased from MedChemExpress. Usage Cited in: Mol Pain. 2025 Jan-Dec:21:17448069251376198. [Abstract]

Injection of mTOR agonist L-leucine induced an upregulation of the protein expression of BDNF in the spinal cord of mice. (Adult male CD-1 mice, KU-0063794 was administered intraperitoneally (i.p.) at 8 mg/kg, L-leucine was administered i.p. at 50 mg/kg).

L-Leucine purchased from MedChemExpress. Usage Cited in: Mol Pain. 2025 Jan-Dec:21:17448069251376198. [Abstract]

Pharmacological S6K1 inhibition by PF-4708671 significantly reversed L-leucine-induced thermal hyperalgesia. (Adult male CD-1 mice, 50 mM PF-4708671 (0.5 mL) was injected i.p. at 40 mg/kg per mouse, L-leucine was administered i.p. at 50 mg/kg).
Pulm Circ

High gestational leucine level dampens WDPCP/MAPK signaling to impair the EMT and migration of cardiac microvascular endothelial cells in congenital heart defects. [Abstract]

2024 Nov 21;14(4):e70013. PMID: 39582775
Amino Acids

Identification of amino acids metabolomic profiling in human plasma distinguishes lupus nephritis from systemic lupus erythematosus. [Abstract]

2024 Sep 18;56(1):56. PMID: 39292313
bioRxiv

2025 Aug 19.
Research Square Preprint

2021 Jul.

Solvent & Solubility

In Vitro:

H₂O : 8.33 mg/mL (63.51 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

7.6237 mL

38.1185 mL

76.2369 mL

5 mM

1.5247 mL

7.6237 mL

15.2474 mL

10 mM

0.7624 mL

3.8118 mL

7.6237 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 6.25 mg/mL (47.65 mM); Suspended solution; Need ultrasonic and warming and heat to 60°C

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Portuguese - PT (254 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Baoshan Xu, et al. Stimulation of mTORC1 with L-leucine rescues defects associated with Roberts syndrome. PLoS Genet. 2013;9(10):e1003857. [Content Brief]

[2]. Bruckbauer A, et al. Synergistic effects of leucine and resveratrol on insulin sensitivity and fat metabolism in adipocytes and mice. Nutr Metab (Lond). 2012 Aug 22;9(1):77. [Content Brief]

[3]. Rachdi L, et al. L-leucine alters pancreatic β-cell differentiation and function via the mTor signaling pathway. Diabetes. 2012 Feb;61(2):409-17. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	7.6237 mL	38.1185 mL	76.2369 mL	190.5924 mL
	5 mM	1.5247 mL	7.6237 mL	15.2474 mL	38.1185 mL
	10 mM	0.7624 mL	3.8118 mL	7.6237 mL	19.0592 mL
	15 mM	0.5082 mL	2.5412 mL	5.0825 mL	12.7062 mL
	20 mM	0.3812 mL	1.9059 mL	3.8118 mL	9.5296 mL
	25 mM	0.3049 mL	1.5247 mL	3.0495 mL	7.6237 mL
	30 mM	0.2541 mL	1.2706 mL	2.5412 mL	6.3531 mL
	40 mM	0.1906 mL	0.9530 mL	1.9059 mL	4.7648 mL
	50 mM	0.1525 mL	0.7624 mL	1.5247 mL	3.8118 mL
	60 mM	0.1271 mL	0.6353 mL	1.2706 mL	3.1765 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

L-Leucine

Metabolism/Protease Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Autophagy Compound Library

Human Endogenous Metabolite Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Ubiquitination Compound Library

NMPA-Approved Drug Library

Medicine Food Homology Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Pancreatic Cancer Compound Library

Gut Microbial Metabolite Library

Anti-Cancer Metabolism Compound Library

Microbial Metabolite Library

Angiogenesis-Related Compound Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Food Additive Library

Food-Sourced Compound Library

Inactive Ingredient Library

Targeted Diversity Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

E3 Ligase Ligand Library

Anti-Aging Natural Product Library

Pain-Related Compound Library

Off-patent Drug Library

Animal-Sourced Natural Product Library

Highly Selective Activators Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Dietary Supplement Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Endogenous Metabolite Library

Mass Spectrometry Human Metabolite Library

Mouse Metabolite Compound Library

Amino Acid Metabolite Compound Library

20 Amino Acids Library

Mongolian Medicine Compound Library

Chinese Baijiu Compound Library

Flavors and Fragrances Compound Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) L-Leucine

All mTOR Isoforms

All Endogenous Metabolite Isoforms

All Ligands for E3 Ligase Isoforms

Biological Activity

Chemical Information

Publications (16)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table